Alzheimer’s Player Satori Wades Into Fray With Mystery Technology – And $22 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
“Year or two” of pre-IND work lies ahead with new amyloid approach, CEO says.
You may also be interested in...
Amyvid Approval Just The Start Of A Critical Year For Alzheimer’s
One way or another, it is an important time in the Alzheimer’s disease space. Two potential disease altering therapies are set to divulge Phase III results that will answer important questions about the course of the illness, whether they are successful or not, and a promising cognition booster may get the Phase II readout it needs to head into a pivotal trial.
Financings Of The Fortnight: Big FOPO For Troubled Alnylam, Plus First European IPO Of 2012 For Adocia
Plus news on recent financing by Satori, Ceptaris, Vernalis and Exelixis
Investors Lend Satori $15 Million, Hoping It Converts To An Alzheimer's Treatment
The venture-backed Cambridge, Mass. firm says it can get its small-molecule gamma-secretase modulator into the clinic next year.